(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
5 days till quarter result
(tns 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics...
Stats | |
---|---|
Šios dienos apimtis | 3 363.00 |
Vidutinė apimtis | 86 042.00 |
Rinkos kapitalizacija | 3.83M |
EPS | $0 ( 2024-04-03 ) |
Kita pelno data | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.190 |
ATR14 | $0.00500 (13.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-27 | Scott John K Jr. | Buy | 64 289 | Series J Convertible Preffered Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 270 | Series G Redeemable Preferred Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 400 | Series I Convertible Preferred Stock |
2023-11-16 | Moss Dana J | Buy | 416 667 | Common Stock |
2023-11-16 | Moss Dana J | Buy | 200 000 | Common Stock |
INSIDER POWER |
---|
99.85 |
Last 95 transactions |
Buy: 26 134 406 | Sell: 71 109 |
Navidea Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Navidea Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $65 652.00 |
Bruto pelnas: | $-119 295 (-181.71 %) |
EPS: | $-0.590 |
FY | 2022 |
Pajamos: | $65 652.00 |
Bruto pelnas: | $-119 295 (-181.71 %) |
EPS: | $-0.590 |
FY | 2021 |
Pajamos: | $45 615.00 |
Bruto pelnas: | $45 615.00 (100.00 %) |
EPS: | $-0.400 |
FY | 2020 |
Pajamos: | $118 725 |
Bruto pelnas: | $117 677 (99.12 %) |
EPS: | $-0.480 |
Financial Reports:
No articles found.
Navidea
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.